Samsung Biologics
Update in progress207940.KS (KSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Samsung Biologics Co., Ltd. and its subsidiaries manufacture, commercialize and distribute biopharmaceuticals worldwide. It provides development services—late discovery, cell line, process and analytical development—and non-GMP/CGMP manufacturing, plus aseptic filling, lyophilization, cold-chain storage, regulatory support, and quality testing (IPC, stability, release, environmental monitoring, biosafety). It also develops antibody-drug conjugates and mRNA products. Founded 2011, based in Incheon.
Company score
- Sentiment
- 1.61
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.06
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.99
- Governance
- 0.41
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.36
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.98
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketKSE (KSC)
- LocationSouth Korea
- CEOMr. John Chongbo Rim
- Founded2011
- Employees5,326
- Websitesamsungbiologics.com
Identifiers
- ISINKR7207940008